Objectives: Researchers have recently investigated the biological activities of mesoionic (MI) compounds, which have shown in vitro activity against many species of Leishmania, as well as Trypanosoma cruzi. The main goal of this study was to evaluate and compare the activity of three MI compounds against Leishmania amazonensis and Leishmania infantum infection in vivo.
Introduction
Leishmaniasis represents a set of important human diseases that produce different clinical manifestations depending on the Leishmania species involved and the host immune response. The two general forms of the disease, which are caused by several species of Leishmania, are visceral leishmaniasis (VL) and tegumentary leishmaniasis (TL).
Furthermore, these diseases constitute the third largest group of vector-transmitted infectious diseases, behind malaria and filariasis, 1 and they belong to the group of neglected tropical diseases with research priority according to the WHO. Leishmaniasis affects approximately 12 million people worldwide; the annual incidence of new cases is approximately 2 million, and 350 million people are at risk for infection. 2 There are 500 000 new cases of VL per year globally, although 90% of these new cases occur in just five countries (India, Bangladesh, Brazil, Nepal and Sudan). Tegumentary forms of the disease affect 1 500000 people worldwide, and although TL is not a lethal disease like VL, disfigurement, disability, and social and psychological stigma are all severe consequences of TL.
In South American countries, Leishmania amazonensis causes a broad spectrum of clinical manifestations; these range from single to multiple cutaneous lesions and include disfiguring nodules associated with the mucosal form of the disease as well as visceral complications. 3, 4 This species is described as the unique aetiological agent of anergic diffuse cutaneous leishmaniasis in Brazil. This condition is associated with the specific impairment of the cell-mediated immune response at the early stage of infection. Furthermore, diseases caused by this parasite display little to no tendency to self-cure.
However, human infections with Leishmania infantum (syn Leishmania chagasi), 5 the protozoan causing South American VL, range from subclinical to progressive fatal disease. In southern Europe, VL is an opportunistic infectious disease mainly affecting patients treated with immunosuppressive agents or infected with HIV. The number of VL/HIV co-infection cases reported in Spain, France, Italy and Portugal has increased. 6 Thus, improvements to the therapeutic regimen, the quality of diagnosis and disease control are needed.
In light of the current clinical scenario, the development of new drugs is desirable. Since the 1950s, pentavalent antimonials have been the recommended drugs for the treatment of leishmaniasis, although amphotericin B and its formulations, aminosidine and pentamidine have also been used. These therapies are not ideal due to toxicity, the long duration of administration and the high cost. Furthermore, reports have indicated that a large proportion of cases have become unresponsive to traditional chemotherapy. 7 In addition, the participation of the host immune response may negatively affect treatment and disease progression. Several new antileishmanial compounds are under development, although a drug with the capacity to completely cure this infection has yet to be discovered. 8 Therefore, there is an urgent need to discover novel agents, as the efficacy of the currently available drugs is declining.
In an effort to find new drugs for leishmaniasis, our research has focused on mesoionic (MI) compounds. In previous work we synthesized salts of MI derivatives of the 1,3,4-thiadiazolium-2-aminide class and assayed their activity against L. amazonensis, Leishmania braziliensis and L. chagasi and their effect on murine macrophage cytotoxicity. 9, 10 Certain MI derivatives were also tested for their activity against cutaneous leishmaniasis in vivo caused by L. amazonensis. 11 The chemical structure of the MI compounds contains defined regions of positive and negative charge and is associated with a polyheteroatomic system, which enables these compounds to interact with biomolecules. Although the molecules are internally charged, they have a neutral overall charge and can therefore cross biological membranes. These characteristics have been highlighted by the interesting biological activities of these compounds, which include their anti-inflammatory, analgesic, antibacterial, antifungal and antitumour activities. 12, 13 In addition, each class of MI compound has received considerable attention and has been extensively studied because of their unique structure, reaction behaviour and biological activity, as well as their potential medicinal properties as potent antiplatelet, fibrinolytic and broncholytic agents. 13 -16 These effects may be directly related to the presence of specific substituent groups on the molecular ring or to the ability of the structure to release nitric oxide ( † NO). 17 In addition, high concentrations of † NO in macrophages have been identified as a potent effector mechanism that targets the intracellular forms of Leishmania.
Based on this information on MI compounds, we assayed three MI derivatives (MI-HH, MI-4-OCH 3 and MI-4-NO 2 ) for their activity against L. amazonensis cutaneous leishmaniasis and L. infantum visceral leishmaniasis. These studies used BALB/c mice and alternative routes of administration depending on the infection. The cutaneous form was treated topically or intralesionally, and the visceral form was treated intraperitoneally.
Materials and methods

MI compounds
The preparation of the 4-phenyl-5-(4-H-, 4-OCH 3 -or 4-NO 2styryl)-1,3,4-thiadiazolium-2-phenylamine chlorides was carried out according to published procedures. 9 These derivatives were fully characterized by infrared (IR), 1 H, 13 C NMR spectroscopy and mass spectrometry. The compounds were solubilized in DMSO (the highest concentration used was 1.6% v/v).
Mice
Inbred BALB/c mice at 6 -8 weeks of age (25 -30 g body weight) were provided by the mouse breeding facility at the CECAL (Centro de Criaçã o de Animais de Laborató rio) of FIOCRUZ (Rio de Janeiro, Brazil). All recommendations by national law (no. 6638,05/11/1979) for the scientific management of animals were respected, and the experiments were conducted using a protocol approved by the Comissã o de Ética no Uso de Animais CEUA/Fiocruz (P0020-00).
Parasites
L. amazonensis (MHOM/BR/LTB0016) and L infantum (MHOM/ MA67ITMAP263) were maintained by periodic passages in BALB/c mice. L. amazonensis promastigotes were grown at 268C in Schneider's Drosophila medium (Sigma) supplemented with 10% fetal calf serum (FCS) at a pH of 7.2. L. infantum promastigotes were cultivated in Roswell Park Memorial Institute (RPMI) medium (Sigma) supplemented with 10% FCS and 2 mM L-glutamine at 268C. Parasites were harvested from the stationary phase and used to infect mice.
Infection and mouse treatment
L. amazonensis infection and treatment regimen
Mice were injected in the footpad with 1×10 6 promastigotes of L. amazonensis. After 4 weeks the mice received a single daily dose of the MI compound (MI-HH, MI-4-OCH 3 or MI-4-NO 2 ) subcutaneously in the footpad. The treatment lasted for 4 weeks, which consisted of 5 days of treatment followed by 2 days of rest. Animals in the control group received equivalent volumes of the vehicle as treatment animals (saline/ DMSO; Sigma). Meglumine antimoniate, a classic antileishmanial drug, was used as a reference. The concentrations of the drugs administered were as follows: 28 mg Sb(V)/kg/day for meglumine antimoniate, 18, 19 24 mg/kg/day for MI-H-H, 22 mg/kg/day for MI-4-OCH 3 , 13 and 20 mg/kg/ day for MI-4-NO 2 .
In the treatment regimen for L. amazonensis infection, the MI derivatives were used in a topical formulation at 1% of the concentrations listed above. This formulation was prepared using diadermine cream as an inert vehicle. Four weeks after infection the mice received topical cream on the entire infected footpad once a day, 5 days per week. During this application it was necessary to massage the cream into the footpad and to wait for the cream to be absorbed. Animals in the control group received the same volume of the vehicle (diadermine/DMSO).
L. infantum infection and treatment regimen
Mice were injected with 1×10 8 promastigotes of L. infantum intraperitoneally. Seven days after infection the mice received a single daily dose of the MI compound (MI-HH, MI-4-OCH 3 or MI-4-NO 2 ) intraperitoneally. The treatment lasted for 4 weeks, which consisted of 2 days of rest following 5 days of treatment. Animals in the control group received the same The effect of mesoionic compounds against leishmaniasis 183 JAC volume of the vehicle (saline/DMSO). Meglumine antimoniate, a classic antileishmanial drug, was used as a reference. The concentrations of the drugs used for treatment were as follows: 28 mg Sb(V)/kg/day for meglumine antimoniate, 18, 19 24 mg/kg/day for MI-HH, 22 mg/kg/day for MI-4-OCH 3 , 13 and 20 mg/kg/day for MI-4-NO 2 .
Measurement of cutaneous lesion size
At different times after L. amazonensis infection (4, 6, 8, 9, 10, 11 and 12 weeks post-infection), the footpad swelling was measured using a dial caliper (Mitutoyo). This value was expressed as the difference in the thicknesses in millimetres between the inoculated footpad and the median of the five footpads in the control group.
Parasite load in the lymph node and spleen
The parasite load was estimated using a parasite-limiting dilution assay. To evaluate the parasite load in mice with cutaneous leishmaniasis 4 weeks after the end of treatment, the animals were euthanized in a CO 2 chamber, and the draining lymph nodes and spleen were aseptically removed, weighed and homogenized in Schneider's medium supplemented with 10% FCS (Sigma). To evaluate the parasite load in mice with the visceral form, the spleen and liver were prepared as described above, but these mice were sacrificed directly following the end of treatment. Briefly, 10-fold serial dilutions were prepared and distributed to 96-well microtitre plates in triplicate and under sterile conditions. During the 7 day incubation at 268C, the wells were examined daily using an inverted microscope. The number of parasites per milligram of tissue was estimated based on the tissue weight and the parasite load from the culture dilutions, and this quantification followed the method described by Taswell. 20,21
Evaluation of MI compound toxicity in mice
At the end of the treatment period, blood samples were taken from the tails of control and infected animals either treated or untreated with the MI compounds. The white blood cell percentages were estimated by staining with the InstantProv kit (Newprov). The sera were assayed colorimetrically for levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine.
Antibody profile
High-binding ELISA plates (Falcon) were coated overnight at 48C with 50 mg/mL Leishmania sp. antigen in PBS. Plates were washed three times with PBS containing 2% FCS (Cultilab) and blocked with PBS containing 10% FCS for 1 h at room temperature. The sera were diluted in PBS containing 10% FCS (1:50) and were added in triplicate and incubated for 1 h at 378C. The peroxidase-conjugated goat anti-mouse immunoglobulins (BD Biosciences; IgM and IgG) were diluted in PBS (1: 4000) and added to the plate for 1 h at 378C. The tetramethyl benzidine (TMB; Zymed) substrate was added at 100 mL/well to detect peroxidase activity. The plates were incubated for 15 min in the dark at room temperature. The reaction was then blocked with 3N H 2 SO 4 , and the absorbance was read at 450 nm.
Cell culture and evaluation of cytokines in supernatants
For L. amazonensis infection, the draining lymph nodes and spleens were excised and prepared for culture 4 weeks after the end of treatment. For L. infantum infection, spleens were excised 1 day after the last administration of the drug. For both infections, the organs were weighed and pooled into single cell suspensions as previously described. 22 Cells were washed and resuspended at 3×10 6 cells/mL in RPMI culture medium supplemented with 10% FCS (Sigma), 2 mM L-glutamine, 100 U of penicillin/100 mg/mL streptomycin, 25 mM HEPES, 3.7 g/L sodium bicarbonate (Sigma) and 25.4 mM sodium pyruvate (GIBCO). To assay cytokine production, cells were added to 24-well tissue culture plates (Costar) at 3×10 6 cells/mL in a total volume of 1 mL. L. infantum or L. amazonensis antigens (50 mg/mL) were used to stimulate the cell cultures in the presence or absence of 10 mg/mL concanavalin A (ConA; Sigma). Control cultures containing no parasite antigen or ConA alone (positive control) were also prepared. After 48 h of stimulation, culture supernatants were harvested and used to determine interferon-gamma (IFN-g), interleukin-4 (IL-4) and interleukin-10 (IL-10) levels by ELISA. Individual cytokine antibodies were used to coat the ELISA plates (Maxisorp) and non-specific binding sites were blocked with PBS containing 10% FCS. Cytokine standards (IFN-g, IL-4 and IL-10; BD Pharmigen) or culture supernatants were added to the designated wells (50 mL/well) and incubated overnight at 48C. Binding was detected using the appropriate biotinylated anti-cytokine capture antibodies (BD Pharmigen) and the addition of streptavidin-horseradish peroxidase (BD Pharmigen) and the substrate TMB. The reaction was blocked with 3 N H 2 SO 4 , and the absorbance was measured at 450 nm. † NO dosage † NO is quickly degraded into nitrite and nitrate, therefore the nitrite concentration was determined using the Griess reaction. † NO production was assayed, after 48 h of incubation, by measuring the concentration of nitrite present in the supernatants of the lymph node and spleen cell cultures by the Green method. 23 Fifty microlitres of cell culture supernatant was incubated with an equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylenediamine dihydrochloride and 2.5% orthophosphoric acid) for 10 min at room temperature. The absorbance was measured spectrophotometrically at a wavelength of 540 nm using a blank that consisted of medium plus Griess reagent (v/v). The results were expressed as millimoles NO 2 based on the standard curve of known concentrations of sodium nitrite (NaNO 2 ) dissolved in medium.
Statistical analysis
Statistical analysis was performed using a one-way and two-way analysis of variance (ANOVA) to test for statistical significance (GraphPad Prism; GraphPad Software, La Jolla, CA, USA). A P value of ≤0.05 was considered statistically significant. Three separate experiments were performed.
Results
Differences in the efficacy of topical and intralesional treatment with MI compounds on the experimental infection with L. amazonensis
This study utilized a high-sensitivity murine model of L. amazonensis infection to evaluate the therapeutic activity of MI compounds, the subsequent alterations of the host immune response and the toxicity of this treatment in mice.
The results found that the surface area of the cutaneous leishmaniasis (CL) lesions increased in the 4 weeks after infection. Intralesional or topical treatment with the MI compounds MI-4-OCH 3 and MI-4-NO 2 efficiently controlled the growth of the lesions. Meglumine antimoniate (intralesional) also demonstrated therapeutic activity in this model. Four weeks after the end of treatment, there was a statistically significant reduction in lesion size in the treated mice (Figure 1a and b) , while the lesion growth continued in the control group (P,0.05). The examinations found that the use of topical formulations of MI-4-OCH 3 and MI-4-NO 2 showed Rodrigues et al.
greater efficacy in the regulation of the surface area of the cutaneous lesions (P,0.005). Intralesional treatment with the MI compounds MI-4-OCH 3 and MI-4-NO 2 was more efficient than meglumine antimoniate treatment at 12 weeks post-infection (P,0.05). The intralesional or topical treatment with MI-HH did not show therapeutic activity for improving the lesion size.
Many mice given intralesional treatments were found to have ulcers (control or not), while only control animals or those in the MI-HH group given topical treatments were found to have ulcers in the footpad. Table 1 shows the parasitic load from the different tissues (footpad, draining lymph nodes and spleen) used by L. amazonensis to infect and disseminate within the host animal. Each of the treatments (MI-HH, MI-4-OCH 3 , MI-4-NO 2 or meglumine antimoniate) was found to decrease the parasitic load following administration by either the intralesional or topical route. However, there were differences in their antileishmanial efficacies in different organs.
In the footpad, meglumine antimoniate was most effective in decreasing the parasite load in the lesion (P ≤ 0.005), although the MI-4-OCH 3 and MI-4-NO 2 treatments reduced the parasite load more effectively than the control treatment (P ≤ 0.005) and both routes of administration were equally effective. In the draining lymph nodes, the intralesional treatment with meglumine antimoniate or MI-4-NO 2 had similar efficacy as the topical treatment with MI-4-OCH 3 and MI-4-NO 2 . In the spleen, MI-4-OCH 3 and MI-4-NO 2 treatments were found to completely interrupt parasite dissemination, as no parasites were isolated from this organ. Interestingly, meglumine antimoniate treatment was not as effective at blocking this migration, as parasites were isolated from spleen. However, this treatment was significantly more effective (P ≤ 0.005) than the control treatment. In addition, both routes of treatment with MI-HH were able to reduce the parasite load in all tissues, but this reduction was less than for the other compounds tested.
Based on the toxicity parameters analysed in this study, there were no indications of any alterations ( Table 2 ). The haematological white blood cells counts were not altered by treatment, as noted in Table 2 . Lymphocytes, neutrophils and monocytes were differentially analysed and counted, and there were no statistically significant differences observed following treatment (data not shown).
The hepatic enzymes AST and ALT and creatinine levels were analysed from the sera of the mice at the end of the treatment period (8 weeks post-infection). Intralesional treatment with meglumine antimoniate correlated with greater levels of AST and creatinine than did the control treatment (P≤ 0.05). Treatment with the MI compounds did not result in alterations of these levels. In addition, no behavioural changes or changes in weight were noted in mice infected and treated.
This study evaluated certain aspects of the murine immune response, including the concentrations of NO, IFN-g, IL-4, IL-10 and IgG and IgM antibodies. Figure 2(a and b) shows the profiles of cytokine levels from the supernatants of the draining lymph node cells stimulated with either ConA or L. amazonensis antigen. The production of NO was not altered by the treatments (data not shown). The concentration of IFN-g was greater following the MI-4-OCH 3 , MI-4-NO 2 or meglumine antimoniate treatments (both routes) in comparison with the control (P ≤0.05).
Interestingly, intralesional treatment with MI-4-NO 2 was found to increase the level of IL-4 and decrease the level of IL-10 (P ≤ 0.05), but topical treatment was not found to change these levels. In addition, intralesional treatment with MI-4-OCH 3 decreased IL-10 levels and did not change IL-4 levels, which is the opposite of the results seen after topical treatment (decreased IL-4 and no changes in IL-10).
The serum antibody levels (IgG and IgM) are shown in Figure 3(a and b) . There were increased IgG levels in the groups treated with MI-4-OCH 3 , MI-4-NO 2 (both routes) and meglumine antimoniate compared with controls (P ≤0.05) at the end of treatment (8 weeks post-infection). Low IgM levels were found in all groups at 4 and 8 weeks post-infection.
The efficacy of intraperitoneal treatment with MI compounds on experimental infection with L. infantum
This is the first report on the therapeutic efficacy of MI compounds in the treatment of visceral leishmaniasis. The factors controlling this disease are different from those controlling CL.
For this infection, the therapeutic activity was evaluated by comparing the parasite load in the spleen and liver.
As seen in Table 1 , intraperitoneal treatment with MI-4-NO 2 efficiently controlled the disease; no parasites were isolated from spleens or livers of mice infected with L. infantum after 4 weeks of treatment. Treatment with MI-4-OCH 3 or meglumine antimoniate decreased the parasite load in the spleen in comparison with the control (P ≤ 0.005), and no parasites were isolated from the liver. In addition, MI-HH treatment decreased the parasite load in the spleen as effectively as meglumine antimoniate, although parasites were isolated from the liver following treatment.
As demonstrated for L. amazonensis infection, toxicological aspects were evaluated at the end of treatment in mice infected with L. infantum ( Table 2 ). Meglumine antimoniate treatment resulted in changes in the serum AST concentration and creatinine level (P ≤ 0.05). However, treatment with MI-4-NO 2 also resulted in greater AST concentrations than did the control treatment (P ≤ 0.05). During the 5 weeks of the experiment, there were no behavioural or body weight changes observed in the mice.
Changes in the immune response, including alterations in NO level and cytokine release, were analysed following the stimulation of spleen cells with ConA or L. infantum antigens (as shown in Figure 2c ). Following treatment, the NO levels did not change (data not shown), but the levels of IFN-g, IL-4 and IL-10 produced following stimulation were altered. Treatment with MI-4-OCH 3 or MI-4-NO 2 increased the IFN-g concentration (P ≤ 0.005) and decreased the IL-4 and IL-10 concentrations in comparison with the controls (P ≤0.005 and P ≤ 0.05, respectively). Treatment with meglumine antimoniate decreased the levels of IL-10 produced (P ≤ 0.05), and treatment with MI-HH did not alter any of these values.
The IgG and IgM levels from the sera of mice infected with L. infantum are shown in Figure 3 (c). There was no fluctuation in IgG levels in any of the treatment or control groups (1 and 5 weeks post-infection). However, lower IgM levels were noted at 5 weeks post-infection in the mice treated with MI-4-OCH 3 , MI-4-NO 2 and meglumine antimoniate compared with the controls (P ≤ 0.05).
Discussion
The cutaneous and visceral forms of leishmaniasis remain therapeutic challenges and serious public health problems. Pentavalent antimonials are the most commonly used drugs for the treatment of leishmaniasis, although the existence of drug-resistant infections and the fact that these drugs need to be administered parenterally represent major limitations for leishmaniasis chemotherapy. Unfortunately, ideal therapies for leishmaniasis have yet to be identified. 24 The first topical drugs used against cutaneous leishmaniasis, imiquimod 25 and paromomycin, 26 are at the same phase of clinical testing. The most significant result from this study, in terms of the cutaneous form of the disease, was that topical treatment with MI compounds was effective in a highly susceptible murine model. Furthermore, intraperitoneal treatment with MI-4-NO 2 was shown to effectively control visceral leishmaniasis. The previously described in vitro and in vivo activities of these MI 13 Previous work from our group demonstrated that MI derivatives inhibit the in vitro growth of L. amazonensis promastigotes and axenic amastigotes. 9 Consequently, MI-HH and MI-4-OCH 3 were evaluated for efficacy in L. amazonensis infection in CBA/J mice. 11 In the present study we have shown the effects of three substituted MI compounds (MI-HH, MI-4-OCH 3 and MI-4-NO 2 ) used to treat susceptible BALB/c mice infected with L. amazonensis or L. infantum.
The murine model of leishmaniasis has been extensively studied, and it is generally accepted that cell-mediated immunity plays a causal role in host resistance to infection. Accordingly, this murine system provides a convenient and biologically relevant model to investigate the immunological parameters influenced by the application of diverse compounds. In general, the involvement of T helper 1 (Th1) and T helper 2 (Th2) subsets in the protection or exacerbation of disease has been demonstrated in murine TL. 27 However, the Leishmania species may influence the immune response, as L. amazonensis infection causes a mixed Th1/Th2 response. 28, 29 In this study, high concentrations of IFN-g were observed following treatment with MI-4-OCH 3 , MI-4-NO 2 or meglumine antimoniate for L. amazonensis infection and these values were correlated with decreased lesion size and parasite load. However, the IL-4 concentrations varied according to MI compound and the routes of administration and therefore do not explain these effects. Low levels of IL-10 were observed in the groups treated with MI compounds and that contained the lesion growth and had high production of IFN-g.
A similar pattern of Th cell subset-associated cytokines has been shown for VL, and this is most likely due to the ability of IL-4 to regulate macrophage function. 30 Unexpectedly, some studies in animal models have shown that protection against VL is associated with the production of both Th1 and Th2 cytokines. 31 -33 However, in the models used in this study, increased levels of Th1 cytokines were associated with a positive therapeutic response following treatment with the MI compounds MI-4-OCH 3 and MI-4-NO 2 and meglumine antimoniate. Cytokines and other mediators released from activated cells, which modify macrophage functions, underscore the complexity of this process.
In general, high levels of antibodies are related to disease progression, as these are involved in the Th2 response and increased B cell function. B cell-derived immunoglobulins (IgM and IgG) have been found to play a critical role in the progression of leishmaniasis, particularly for VL. 34 The persistence of high levels of IgM in the control group until 5 weeks post-infection was an indication of parasite survival and was correlated with the high levels of IL-10 in this group.
The function of NO in the leishmanicidal activity of activated macrophages has been demonstrated. 35 -37 However, the NO production by macrophages does not fully explain the inhibitory effects of the MI compounds on lesion size or parasite load during Leishmania infection. In support of this, only treatment with MI-4-OCH 3 was found to increase the NO concentration, but this increase was not statistically significant. However, these levels were only examined at 12 weeks post-infection, and other timepoints, such as 8 weeks post-infection, at the end of the treatment may better demonstrate this effect.
Given these considerations, further studies will be necessary to elucidate the role of administered MI compounds in the defence against infection. These studies will create new perspectives for the investigation into other mediators and/or cytokines in this process.
This study has shown that MI compounds exhibit significant activity in the treatment of L. infantum infection in mice. Furthermore, MI-4-NO 2 was the most effective compound tested in this model. Whereas intralesional treatment with MI-4-OCH 3 and MI-4-NO 2 had greater therapeutic efficacy than meglumine antimoniate in the L. amazonensis model, the new topical formulations of these compounds also displayed significant activity in the CL model. Upon comparison of these molecules, MI-4-NO 2 was the compound with satisfactory activity in both in vivo models and for all routes of administration tested. However, new topical formulations could be prepared using other vehicles, such as an ethanolic aqueous solution, gentamicin or urea to increase the permeability of these compounds. 38 In conclusion, the lack of apparent toxicity, as demonstrated by serum analyses, as well as the protective in vivo effect on murine leishmaniasis (CL and VL) encourage further studies of these MI derivatives, including MI-4-OCH 3 and MI-4-NO 2 , as new antileishmanial drugs. Studies on the pharmacokinetics, dosage optimization and mechanism of action of these compounds in relation to their antileishmanial activity should be carried out to determine an adequate dosing regimen and administration routes for therapeutic use.
